Their study involving 44 patients with advanced HCC who received sorafenib showed that the expression levels of myeloid cell leukemia-1 (Mcl-1) and pERK were associated with reduced OS through the expression of Mcl-1, activated/phosphorylated extracellular signal-regulated kinase (pERK) 1/2, and activated/phosphorylated AKT (pAKT) in pretreatment tumor specimens (39). The gene discussed is MCL1; the disease is hepatocellular carcinoma.